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Migraine is a common health problem in children and adolescents (1-3). It can 
negatively affect children and adolescents in their daily activities and school 
performances as well as causes school absenteeism (3,4). The mean age for the 
onset of migraines varies in children with gender, and is reported to be 7.2 years 
in boys and 10.9 years in girls 5, 6. The prevalence of migraine headaches among 
children and adolescents aged between 5 to 15 years ranged from 2.7–10.6% 3. The 
prevalence increases with age and is reported to be up to 28% in adolescents, aged 
15 to 19-years 3, 7. Migraine headaches show a male predominance in children, 
which shifts to a slight female predominance in adolescence that continues into 
adulthood (3, 5).
Management of migraine headaches in children and adolescents consists of bio-
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Migraines, a common health problem in children and adolescents, still do not 
have an FDA approved preventive treatment for patients under the age of 18 
years. This study compares and contrasts the efficacy and safety of cinnarizine 
and topiramate in preventing pediatric migraines.
Materials & Methods 
 In this randomized, double-blind clinical trial 44 migrainous (from 4–15 years 
of age) were equally allocated to receive cinnarizine or topiramate. The primary 
efficacy measure was monthly migraine frequency. Secondary efficacy measures 
were monthly migraine intensity and ≥ 50% responder rate. Efficacy measures 
were recorded at the baseline and at 4, 8, and 12 weeks of treatment. 
Results
During the double-blind phase of the study, monthly migraine frequency and 
intensity were significantly decreased in both the cinnarizine and topiramate 
groups when compared to the baseline. However, at the end of the study, the 
cinnarizine group exhibits a significant decrease from the baseline in the mean 
monthly migraine intensity when compared to the topiramate group (4.7 vs. 3, 
respectively; 95% CI = -0.8 to -3.2).
Conclusion 
No significant difference between cinnarizine and topiramate was found for the 
prevention of pediatric migraines. Both treatments were well tolerated. 
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behavioral treatments (including life style changes, 
stress management, and bio-feedback strategies), acute 
treatments, and preventive treatments 8). Preventive 
management is recommended when the frequency 
of migraine attacks is three or more per month or the 
migraine attacks are significantly disabling (as assessed 
by a scoring system such as the Pediatric Migraine 
Disability Assessment Scale) (9, 10). No medications 
are currently approved by the Food and Drug 
Administration (FDA) for the preventive treatment of 
migraine headaches in patients under the age of 18 years 
(8). The preventive treatment of migraines in children 
and adolescents is based on information extracted from 
adult trials on migraines.
Topiramate has been approved for use of migraine 
prevention in adults in Europe and by the FDA (11). Two 
randomized, double-blind, placebo-controlled studies 
show the effectiveness of topiramate in significant 
reduction of monthly migraine frequency in children and 
adolescents (12,13). In another randomized, double-blind, 
placebo-controlled trial, topiramate effectively reduced 
the mean of monthly migraine frequency in children and 
adolescents; however, it didn’t reach significance and the 
results trend was towards significance (14). According  a 
pooled analysis of three pivotal trials, topiramate might 
reduce migraine frequency in adolescents (15). Some 
other uncontrolled studies also showed the effectiveness 
of topiramate in reducing monthly migraine frequency 
in children (16-19). The frequency of side effects varied 
considerably among previous studies with the most 
frequent side effects reported as weight loss, anorexia, 
abdominal pain, sedation, paresthesia, and difficulties in 
concentration (12-19).  
The limited effectiveness of cinnarizine as a preventive 
treatment of migraine headaches in adults is known. Two 
open-label trials and a randomized, double-blind clinical 
trial has shown the effectiveness of cinnarizine treatment 
in reducing the monthly migraine frequency in adults 
(20-22). These studies also reported no serious adverse 
effects (20-22). To the best of our knowledge, no study 
has yet investigated the effectiveness of cinnarizine 
treatment as a prophylaxis for migraine headaches 
among children and adolescents.
To the best our knowledge, no study has compared the 
efficacy and safety of cinnarizine with that of topiramate 
for migraine prevention among children and adolescents. 
In this regard, we conducted a randomized, double-
blind clinical trial to evaluate the efficacy and safety of 
cinnarizine in comparison to topiramate as preventive 
treatments for migraine headaches among children and 
adolescents.
Materials & Methods
We conducted a randomized, double-blind comparative 
trial composed of a prospective baseline lasting for 4 
weeks followed by a double-blind phase lasting for 12 
weeks. 
Patients from 4–17 years of age who were admitted to the 
pediatric neurology clinic of Children’s Medical Center 
Hospital affiliated with Tehran University of Medical 
Sciences with the complaint of headache or diagnoses 
for migraines were evaluated. A complete history of the 
patients’ migraine characteristics as well as a complete 
general medical history was recorded along with a 
general and neurological physical examinations were 
performed. The information collected from recording 
the medical history of patients and their physical 
examinations, patients who met the eligibility criteria 
(including inclusion and exclusion criteria) entered the 
prospective baseline phase of the study. 
The inclusion criteria were as follows:
1. Children and adolescents, Aged 4–17 years, 
diagnosed with migraines (with or without aura) 
according to the International Headache society 
criteria (23);
2. Having experienced one or more migraine attacks 
per month or severe dysfunction in daily and school 
activities; and/ or,
3. Children and adolescents without any known 
structural brain lesions or other systemic conditions 
causing the headaches.
The exclusion criteria were as follows:
1. Diagnosis of chronic headache, complications of 
migraine or migraine variant;
2. Focal neurologic deficit;
3. Severe adverse effects related to the study treatment 
drugs that are listed in the contraindications at the 
beginning or during the double-blind phase of the 
study;
4.  Known concomitant serious disease (hepatic, renal, 
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cardiovascular, or thyroid disease); and/ or,
5. Use of prophylactic migraine therapy in at least one 
preceding month.
In the 4 weeks prospective baseline, the previous 
medications of patients for migraines, either for 
preventive or acute treatment, were halted; and the 
frequency and intensity of the migraines were recorded. 
Each patient was given a diary to record the frequency 
and intensity of each migraine. Patients had to fill out the 
diary every day, whether they experienced migraine or 
not. If they had migraine, they also filled out a checklist 
of headache characteristics attached to the diaries.  
Patients who completed the prospective baseline phase 
of the study entered the 12 weeks double-blind phase 
of the study. At the start of the double-blind phase, 
patients were randomized into two treatment groups. 
One group of participants received cinnarizine as the 
preventive treatment for migraines (the cinnarizine 
group); and the other group of participants received 
topiramate as the preventive treatment for migraines 
(the topiramate group). The study had no placebo group. 
Since the intractable nature of the migraine headaches of 
patients, it was immoral to have a group of participants 
receiving no preventive treatment. In order to maintain 
double blinding, each patient was given an ID code 
and the drugs were given to the patients using their ID 
codes. Cinnarizine and topiramate tablet characteristics 
including the shape, color, and drug packages were 
similar to each other but not the same).
At the start of double-blind phase of the study, a 
blood count test and a liver enzyme test (SGOT) were 
performed. The tests were re-performed at the end of 12 
weeks of the double-blind phase.
In the double-blind phase of the study, there were 
two groups of patients: 1. the cinnarizine group; and 
2. The topiramate group. The cinnarizine group was 
administrated with a dose of 37.5 mg every day for 
patients aged 4–11 years; and 50 mg every day for patients 
aged 12–17 years, from the beginning of the double blind 
phase to the end of the 12 weeks. The topiramate group 
was administrated with a dose of 50 mg every day from 
the beginning of the double blind phase to the end of 
the 12 weeks. Adjustment of the dose of cinnarizine and 
topiramate in presence of intolerability or occurrence of 
serious side effects related to the treatment drugs could 
be considered due to the neurologist of this study’s 
permission. In addition, patients were permitted to take 
analgesics for abortive treatment of acute migraine 
attacks throughout the study. 
Patient information about the characteristics of migraine 
attacks (including the frequency and intensity of attacks) 
during the double-blind phase was recorded using 
diaries. Each patient was provided with a diary for 90 
days, in which all migraine attack characteristics consist 
of the duration  in hours and the intensity of attacks were 
recorded. Parents were also involved by advising them 
to assist their children to correctly fill out the diaries.
Follow up visits were scheduled at 4, 8, and 12 weeks 
during the double-blind phase of the study. At each visit, 
the diaries were checked and collected. Patients were 
evaluated using detailed questionnaires to investigate 
the occurrence of the side effects during the last 4 
weeks (the gaps between visits) and the relation of the 
side effects to the treatment drugs. In this regard, the 
frequency and the occurrence of treatment related side 
effects were assessed. 
Efficacy measures
To measure the efficacy of cinnarizine and topiramate 
treatments, the frequency and intensity of  migraine 
attacks and  50% responder rate to the treatments were 
evaluated. All required data for calculating the intended 
measures were based on information obtained from the 
diaries. 
Frequency of migraine attacks was defined as the mean 
number of migraine attacks that fulfilled the IHS criteria 
for migraine with or without aura 23 per each 4 week 
period. 
The intensity of attacks was measured using the Visual 
Analogue Scale (VAS). This scale consists of a 10 cm 
line that is divided into 10 parts, which are numbered 
0–10. Zero indicates no pain and 10 indicates the worst 
pain imaginable. Migraine intensity was defined as the 
mean intensity of migraine attacks per each 4 week 
period.
A  50% responder rate was defined as the percentage of 
patients who had a migraine frequency that was reduced 
greater or equal to 50%.
Cinnarizine in Preventing Pediatric Migraine
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Safety measures
At each visit of the double-blind phase, safety of the 
treatment drugs was assessed by asking the patients’ 
history of side effects occurrence during the last 4 weeks 
with a detailed questionnaire. The relation of the side 
effects to the treatment drugs was also assessed at each 
visit by interviewing the patients. Special attention was 
paid to the occurrence of sleepiness, decreased appetite, 
and weight loss.
Statistical analysis
Evaluating the efficacy and safety of the treatments was 
based on information obtained from the  diaries, patient 
history (which was recorded at start of the double-blind 
phase and the visits during the double-blind phase), 
general and neurological examinations, and laboratory 
tests (including, blood count and liver function tests). 
Average descriptive statistics and standard deviations 
were provided for the treatment groups separately and 
for the total population. The differences between the 
treatment groups’ baseline characteristics were assessed 
by using two sample (unpaired) t test. The comparison 
between the baseline phase values and 4, 8, and 12 
weeks of treatment during the double-blind phase values 
was performed using sample (paired) t test. In order 
to analyze the treatment comparability, a student’s t 
test for independent samples and analysis of variance 
with repeated measures over time was used. Results 
are expressed as a mean and p<0.05 was considered 
statistically significant. Data were analyzed using SPSS 
software (ver. 18) and confidence interval analysis 
software.
This trial was approved by the ethics committee of 
Tehran University of Medical Sciences. All patients 
were given informed consent about the study prior to 
entering the study.
Results
A total of 40 participants (23 male and 17 female) 
enrolled in the study, with a mean age of 9.0 (range, 
4–15) years. At the baseline, the mean (SD) of monthly 
migraine frequency was 7.7±7.2 and the mean (SD) of 
monthly migraine intensity was 6.9±2.3 (due to VAS 
scaling). Participants were randomly allocated into 
two treatment groups (cinnarizine n=20; topiramate 
n=20). There were no statistically significant differences 
between the treatment groups regarding the participant 
age, the baseline mean of monthly migraine frequency, 
and the baseline mean of monthly migraine intensity 
(p= 0.46, p = 0.81, and p = 0.30, respectively) (Table 1) 
represents demographic data and baseline characteristics 
of the study participants.  
Table1. Demographic Data and Baseline Characteristics of Participants
Cinnarizine Topiramate
Age, 













Mean migraine frequency 
(per month)  SD
8.0 ± 7.98 7.5 ± 6.43
Mean migraine intensity 
(per month) SD
7.3 ± 2.12 6.5 ± 2.42
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Efficacy measures
After 4 weeks of treatment, 35% of the cinnarizine 
group participants and 30% of the topiramate group 
participants showed  50% responder rate; which was 
statistically significant for both groups (p = 0.007, 95% 
CI 0.70-3.90; p = 0.008, 95% CI 0.57-3.33; respectively). 
A significant reduction in the mean of monthly migraine 
intensity for cinnarizine (p < 0.001, 95% CI 1.15-2.25) 
and topiramate (p = 0.002, 95% CI 0.50-1.90) groups 
was also found as opposed to the baseline values.
At the second visit during the double-blind phase (week 
8), statistically significant changes were also observed. 
Both treatment groups showed a statistically significant 
50% responder rate (cinnarizine: 55%, p = 0.004, 95% 
CI 1.26-5.74; topiramate: 50%, p = 0.001, 95% CI 1.70-
5.40). The same was found for the mean of monthly 
migraine intensity (cinnarizine: p < 0.001, 95% CI 2.10-
3.90; topiramate: p < 0.001, 95% CI 1.24-3.16). After 8 
weeks of treatment compared with the baseline values, 
reduction of monthly migraine frequency, and intensity 
demonstrated no statistically significant differences 
between the cinnarizine and topiramate groups (p> 0.05). 
The mean of monthly migraine frequency and intensity 
at the end of the 8th week of treatment in comparison 
to the end of the 4th week significantly lowered within 
treatment groups (p <0.05), but no significant differences 
were found for the cinnarizine versus the topiramate 
group(s) (p> 0.05). 
At the last visit during the double-blind phase (week 12), 
85% of the cinnarizine group and 65% of the topiramate 
group were associated with significant  50% responder 
rate (p= 0.001, 95% CI 2.88-9.12; p= 0.001, 95% CI 
2.18-7.32; respectively). The reduction in the mean 
of monthly migraine intensity was also significant for 
both groups (cinnarizine: p < 0.001, 95% CI 3.67-5.73; 
topiramate: p <0.001, 95% CI 1.80-4.20) compared 
with the baseline values. The reduction of monthly 
migraine frequency showed no significant differences 
for the cinnarizine group versus the topiramate group 
(p> 0.05), whereas monthly migraine intensity in the 
cinnarizine group reached a significant reduction in 
comparison to the topiramate group (p < 0.05). During 
the last 4 weeks of treatment, the reduction in monthly 
migraine frequency and intensity was significant for 
both treatment groups (p<0.05); however, these values 
demonstrated no differences between the cinnarizine 
and the topiramate group (p> 0.05). 
Table 2 shows the mean of monthly migraine frequency 
and intensity in the baseline phase and during the double-
blind phase (after 4, 8, and 12 weeks of treatment) 
regarding the treatment groups.
Figure(s) 1 and 2 show the reduction in the mean of 
monthly migraine frequency and intensity from the 
baseline through the double-blind phase compared to 
the responses to the cinnarizine and the topiramate 
treatments.





Mild treatment related adverse effects were reported in 4 subjects of the cinnarizine group, which was 
mild sleepiness. In the topiramate group, 6 subjects experienced mild treatment related adverse effects 
that included mild sedation (71.4%) and mild appetite decrease (14.3%). One subject in the topiramate 
group had serious adverse effects, which were severe decrease in appetite and weight loss (2 Kg, after 
1-month treatment). The serious adverse effects did not result in withdrawal, but adjustment of the 
dose of topiramate. In total 27.5% of subjects (11/40) experienced mild treatment related adverse 
effects of which the most common was sedation (22.5%) (Table 3).No life-threatening side effects 
were reported during the double-blind phase in both treatment groups. 
The analysis revealed no statistically significant differences between the cinnarizine group and the 
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*P values are measured using sample (paired) t test, from the comparison between baseline phase values and 4, 8, and 12 weeks 
of treatment during the double-blind phase values.





Mild treatment related adverse effects were reported in 4 subjects of the cinnarizine group, which was 
mild sleepiness. In the topiramate group, 6 subjects experienced mild treatment related adverse effects 
that included mild sedation (71.4%) and mild appetite decrease (14.3%). One subject in the topiramate 
group had s rious adverse effects, which were severe decrease in appetite and weight loss (2 Kg, after 
1-month treatment). The serious adverse effects did not result in withdrawal, but adjustment of the 
dose of topiramate. In total 27.5% of subjects (11/40) experienced mild treatment related adverse 
effects of which the most common was sedation (22.5%) (Table 3).No life-threatening side effects 
were reported during the double-blind phase in both treatment groups. 
The analysis revealed no statistically significant differences between the cinnarizine group and the 






































































Cinnarizine in Preventing Pediatric Migraine
24 Iran J Child Neurol. 2014 Autumn Vol 8 No 4 
but adjustment of the dose of topiramate. In total 27.5% 
of subjects (11/40) experienced mild treatment related 
adverse effects of which the most common was sedation 
(22.5%) (Table 3). No life-threatening side effects were 
reported during the double-blind phase in both treatment 
groups.
The analysis revealed no statistically significant 
differences between the cinnarizine group and the 
topiramate group for treatment related adverse effects 
(p= 0.29).
Safety measures
Mild treatment related adverse effects were reported 
in 4 subjects of the cinnarizine group, which was 
mild sleepiness. In the topiramate group, 6 subjects 
experienced mild treatment related adverse effects 
that included mild sedation (71.4%) and mild appetite 
decrease (14.3%). One subject in the topiramate group 
had serious adverse effects, which were severe decrease in 
appetite and weight loss (2 Kg, after 1-month treatment). 
The serious adverse effects did not result in withdrawal, 








Mild sedation 4 (20) 5 (25)
Sever sedation 0 (0) 0 (0)
Mild appetite decrease 0 (0) 1 (5)
Sever appetite decrease 0 (0) 1 (5)
Weight loss 0 (0) 1 (5)
Discussion
In the current study, we evaluated the frequency and 
intensity of monthly migraine attacks in children and 
adolescents aged 4–17 years before and after (during a 
12 weeks treatment period) receiving the cinnarizine or 
the topiramate treatment; and compared the results of the 
treatment groups with each other. We also assessed the 
responder rate to cinnarizine and topiramate treatment 
by comparing with the baseline and every 4 weeks of 
treatment (up to 12 weeks). In addition, frequency of 
probable adverse effects related to the cinnarizine and 
the topiramate treatment and the safety of the treatments 
were evaluated.
We demonstrated that the cinnarizine and topiramate 
treatments resulted in significant reductions in the 
frequency and intensity of monthly migraine attacks 
from the baseline through 12 weeks of treatment. The 
reduction in the mean of monthly migraine frequency 
and intensity showed no significant differences for 
cinnarizine versus topiramate treatments from the 
baseline through 12 weeks of treatment with exception 
that cinnarizine was significantly more effective than 
topiramate in the reduction of monthly migraine intensity 
for the last 4 weeks of double-blind phase compared 
with the baseline. The responder rate (50%) was also 
significant for both treatment groups from the baseline 
through 12 weeks of treatment. With regard to the safety 
measures, both treatments were well tolerated and no 
life-threatening side effects were reported.
Two previous controlled trials and a pooled analysis of 
three pivotal trials have been reported in this study and 
the significant effect of topiramate to reduce monthly 
migraine frequency (12, 13, 15). Another controlled trial 
has reported that the topiramate effect in the reduction 
of monthly migraine frequency was not significant; 
however, the trend of the results was toward significance 
14. A number of uncontrolled trials also supported the 
idea of the effectiveness of topiramate in the reduction 
of monthly migraine frequency (16-19). 
A reported 50% responder rate to the topiramate 
Cinnarizine in Preventing Pediatric Migraine
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our study on the effectiveness and safety of cinnarizine 
as a preventive treatment of migraine headaches among 
children and adolescents are incomparable with the 
limited data of previous studies on the effectiveness of 
cinnarizine in migraine prevention among adults (20-
22). 
A limitation of our study was that it had no placebo 
group. Since our probable participants who met the 
primary criteria to enter the baseline period of the study 
had migraine characteristics that make it impossible to 
manage migraines with using no preventive medications. 
It was immoral to randomize them into an additional 
group in which the participants would receive a placebo. 
In this regard, further studies evaluating the effectiveness 
of cinnarizine and/or topiramate on migraine prevention 
in comparison to a control group (which is receiving a 
placebo) should be conducted. 
There is a lack of evidence in the literature about the 
effectiveness and safety of cinnarizine treatment either 
in children and adolescents or in adults. In addition, 
there is no approved medication yet available for 
migraine prevention in children and adolescents. Further 
open-label and controlled trials should be conducted on 
investigating the effectiveness and safety of cinnarizine 
treatment in migraine prevention with special regard to 
children and adolescents.  
In conclusion, both cinnarizine and topiramate 
treatments demonstrated efficacy in the prevention 
of migraine headaches in children and adolescents. 
Cinnarizine can be considered as an effective and novel 
preventive treatment for pediatric migraines. Overall, 
both treatments were well-tolerated and safe.
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